Compare Supplements

Side-by-side comparison of 1 supplements

Ara3.5

ARA-290

Limited safety

Evidence

Evidence Score3.5/10

Studies: 12

Meta-analyses: 0

Dosage & timing

Dosage:

Investigational. Phase-2 trials used 4 mg/day subcutaneously for ~28 days (a phase-2b dose-ranging trial tested 1, 4 and 8 mg/day; an early pilot used 2 mg three times weekly intravenously). No validated or approved regimen exists.

Best Time:

Any time

Can take on empty stomach

Form:

Subcutaneous injection (cibinetide)

What you'll notice

🎯 Reduced neuropathic-pain symptoms (phase-2)positive

~4 weeks

🌱 Corneal/skin small-nerve-fibre regrowth (surrogate)positive

~4 weeks

📉 Metabolic signal in T2D (preliminary)positive

Weeks

Safety

Limited safety

Contraindications:

Pregnancy / breastfeeding (not studied)
Any use outside a clinical trial or physician supervision (investigational, unapproved)
Known hypersensitivity to the peptide

Drug Interactions:

Erythropoiesis-stimulating agents / EPO
Immunosuppressants

Side Effects:

Injection-site reactionsInfection / contamination from non-sterile grey-market product

Want to compare more supplements?

Loading comparison...